Micronutrient Composition for Joint ECM Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic arthritis are inadequate in providing sustained, effective relief from joint damage and inflammation, affecting millions of people worldwide.
Innovation Solution
A micronutrient composition comprising Vitamin C, Vitamin E, Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle, and Glutamine, administered to reduce pro-inflammatory IL-6 and MMP13 secretion, promoting joint health by enhancing extracellular matrix components like Collagen Type II, Aggrecan, and Hyaluronic Acid production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic arthritis, then some symptomatic relief may be achieved, but sustained effective treatment to mitigate joint damage and inflammation is inadequate
Solution Approach 1:
The patent applies composite materials by combining multiple micronutrients (Vitamin C, Vitamin E, Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle, and Glutamine) into a single composition. This composite approach addresses the inadequacy of single-agent treatments by providing synergistic effects that improve both effectiveness and sustained duration of action for treating chronic arthritis and extracellular matrix dysfunction.
2Object-affected harmful factors
If inflammation is present in arthritic joints, then extracellular matrix dysfunction is aggravated, but reducing inflammation is needed to prevent joint damage
Solution Approach 1:
The patent converts the harmful inflammatory process into a beneficial outcome by using micronutrients that modulate the immune response. The composition includes antioxidants (Vitamin C, Vitamin E, Pycnogenol) and anti-inflammatory agents (Boswellia serrata, Cat's claw, Curcumin) that transform the inflammatory environment into one that protects extracellular matrix components, thereby converting the harmful inflammatory factor into a beneficial protective state.
Solution Approach 2:
The micronutrient composition acts as an intermediary between the inflammatory process and the extracellular matrix. Components like Omega-3 fatty acids, Curcumin, and Boswellia serrata serve as mediators that intervene in the inflammatory pathway, blocking the progression from inflammation to matrix degradation while preserving joint structure and function.
3Adaptability or versatility
If multiple micronutrients are combined to treat extracellular matrix dysfunction, then comprehensive joint health support is provided, but treatment complexity increases
Solution Approach 1:
The patent merges multiple micronutrients with different functions into a single integrated composition. By combining antioxidants, anti-inflammatory agents, ECM building blocks, and metabolic support nutrients into one formulation, the patent simplifies administration while providing comprehensive joint health support, thereby resolving the contradiction between versatility and complexity.
Data Source
AI summary
A micronutrient composition is highly effective in treating joint related inflammation and reducing ECM damaging enzymes in joints. The micronutrient composition comprises of Vitamin C, Vitamin E (D-alpha tocopherol), Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle and Glutamine. The micronutrient composition was most effective in supporting critical cellular mechanisms important for healthy joints-increased production and deposition of important ECM components by synovial cells and chondrocytes under pro-inflammatory conditions (presence of LPS). The micronutrient composition also decreased pro-inflammatory IL-6 and decreased secretion of MMP13, the ECM damaging enzyme in joints.